Vol. 116, No. 9 EnvironewsOpen AccessAlternative Test Models: Ocular Safety Assays Accepted Ernie Hood Ernie Hood Search for more papers by this author Published:1 September 2008https://doi.org/10.1289/ehp.116-a381Cited by:3AboutSectionsPDF ToolsDownload CitationsTrack Citations ShareShare onFacebookTwitterLinked InReddit In a significant step forward for alternative safety test methods designed to reduce, refine, or replace the use of live test animals, the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) recently announced the regulatory acceptance of two new in vitro ocular safety assays by the U.S. Food and Drug Administration, Environmental Protection Agency, and Consumer Product Safety Commission. The acceptance was based on recommendations made by ICCVAM after an extensive evaluation of the methods.The United States tallies an estimated 125,000 eye injuries in the home each year caused by accidental exposure to common household products such as bleach and oven cleaner, according to the American Academy of Ophthalmology. Proper identification and labeling of substances that can damage the eye is one way to combat such injuries. Several agencies require manufacturers to test new products for their potential to cause temporary or permanent blindness, irritation, or other eye injuries.Working with the National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM), ICCVAM evaluated and recommended the bovine corneal opacity and permeability (BCOP) and the isolated chicken eye (ICE) test methods—the first nonanimal ocular safety test methods to be accepted by the regulators. In both cases, the animal eyes used for the tests are slaughterhouse waste, so no animals are euthanized specifically to obtain these tissues. The assays have been in development since the early 1990s.Now that the BCOP and ICE assays have earned regulatory acceptance, they must be considered as the first option for ocular safety testing under the Animal Welfare Act, which requires the consideration of alternative methods before animals are used for procedures that may cause more than slight or momentary pain or distress. “If you get a positive result in either of these assays, you can use that as a positive for the purposes of classifying and labeling [a material] as a severe irritant,” says Marilyn Wind, chair of ICCVAM and a deputy associate executive director with the Consumer Product Safety Commission. “If it’s negative, then [manufacturers] have to go to the next step and test in animals. This eliminates the most corrosive and severe chemicals from having to be tested in animals, so there is a reduction in potential pain and distress.”Although precise numbers are not available for the use of live animals in ocular testing, William Stokes, director of NICEATM and executive director of ICCVAM, estimates that based on the relative distribution of adverse effects, use of the two assays could reduce the use of live animals for eye safety testing by 10% or more. “The overall goal is to come up with an integrated testing strategy using several nonanimal tests that will accurately predict whether chemical products have the potential to damage the eye or not,” he says. ICCVAM and NICEATM are in the process of evaluating other in vitro methods for ocular safety, hoping to eventually eliminate altogether the need for in vivo testing in this realm.In the near term, ICCVAM is working with its counterparts in Europe and Japan to expedite approval of the BCOP and ICE assays at the international level by the 30-member Organisation for Economic Co-operation and Development. This group includes the United States, Canada, Japan, and most of the European Union, where a ban on live animal testing of cosmetic ingredients takes effect in March 2009 and the newly implemented REACH (Registration, Evaluation, Authorisation and Restriction of Chemical Substances) legislation will require testing of thousands of chemicals by 2018.FiguresReferencesRelatedDetailsCited by Ubale R and Addo R (2016) RETRACTED CHAPTER: In Vitro and in Vivo Evaluation of Ocular Drugs and Delivery Systems Ocular Drug Delivery: Advances, Challenges and Applications, 10.1007/978-3-319-47691-9_7, (101-115), . Shafaie S, Hutter V, Cook M, Brown M and Chau D (2016) In Vitro Cell Models for Ophthalmic Drug Development Applications , BioResearch Open Access, 10.1089/biores.2016.0008, 5:1, (94-108), Online publication date: 1-May-2016. Creton S, Dewhurst I, Earl L, Gehen S, Guest R, Hotchkiss J, Indans I, Woolhiser M and Billington R (2009) Acute toxicity testing of chemicals—Opportunities to avoid redundant testing and use alternative approaches, Critical Reviews in Toxicology, 10.3109/10408440903401511, 40:1, (50-83), Online publication date: 1-Jan-2010. Vol. 116, No. 9 September 2008Metrics About Article Metrics Publication History Originally published1 September 2008Published in print1 September 2008 Financial disclosuresPDF download License information EHP is an open-access journal published with support from the National Institute of Environmental Health Sciences, National Institutes of Health. All content is public domain unless otherwise noted. Note to readers with disabilities EHP strives to ensure that all journal content is accessible to all readers. However, some figures and Supplemental Material published in EHP articles may not conform to 508 standards due to the complexity of the information being presented. If you need assistance accessing journal content, please contact [email protected]. Our staff will work with you to assess and meet your accessibility needs within 3 working days.